Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an increasingly important class of oral immunomodulatory drugs used to treat inflammatory bowel disease (IBD), including ulcerative colitis, and GI nurses should be familiar with their mechanism, dosing considerations, and monitoring requirements.
• Because JAK3 signaling is tied to multiple cytokine pathways (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21), patients on JAK inhibitors may be at increased risk for infections, herpes zoster reactivation, and other immune-related adverse events—key points for pre-procedure screening and patient education.
• Understanding that JAK inhibitors are a targeted, mechanism-based therapy (rather than broad immunosuppression) helps nurses explain treatment rationale to patients and reinforces the importance of adherence and lab monitoring (CBC, lipids, liver function).
• As newer JAK-targeted agents move into IBD management, endoscopy nurses will increasingly encounter these medications during pre-procedure medication reconciliation and post-procedure discharge teaching, requiring updated knowledge of holding parameters and interaction risks.

Clinical Relevance

This research summary highlights the foundational science behind JAK3 discovery and its translation into an entire class of immunomodulatory drugs now used across autoimmune diseases, including IBD. For GI and endoscopy nurses, this matters directly at the bedside: patients presenting for colonoscopy, sigmoidoscopy, or capsule endoscopy for IBD surveillance or symptom evaluation may already be on JAK inhibitors such as tofacitinib or upadacitinib. Recognizing these medications on a med list, understanding their immunomodulatory effects, and knowing how they may influence bowel prep tolerance, healing after biopsy, or infection risk during the periprocedural period are all practical extensions of this basic science.

From an operational standpoint, this underscores the value of robust medication reconciliation protocols in endoscopy units. Nurses should be prepared to ask targeted questions about JAK inhibitor use, recent infections, and lab monitoring status, and to communicate any concerns to the proceduralist before sedation and biopsy decisions are made. Additionally, because cytokine-driven inflammation is central to disease activity in IBD, nurses assisting with endoscopic assessment (e.g., Mayo score documentation, biopsy collection for histologic activity) are contributing data that directly ties back to how well these targeted therapies are controlling underlying immune dysregulation.

On the professional development side, this research is a reminder that GI nursing practice is increasingly intertwined with immunology and molecular pharmacology. As JAK inhibitors and related biologic/small-molecule therapies expand into new autoimmune indications, ongoing education—through GI nursing conferences, pharmacy in-services, or IBD center collaboration—will help nurses stay current on emerging drug classes, their side-effect profiles, and their implications for endoscopic care planning, including timing of procedures relative to dosing and immunosuppression status.

Bottom Line

JAK inhibitors, born from foundational discoveries like JAK3 signaling, are now a mainstay immunomodulatory therapy in IBD and other autoimmune diseases—GI nurses should know these medications by name, understand their infection and monitoring risks, and incorporate them into thorough periprocedural assessment and patient education.